BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income

BeOne Medicines Ltd.

2024-Q3 EPS reported -$0.36 revenue$2,682,417,000

Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).
GAAP operating loss narrowed to $120.3M from $134.0M; adjusted operating income $65.6M vs loss $16.3M.
BRUKINSA global revenue $690M; now #1 in new patient starts for frontline and R/R CLL in U.S.
Four NMEs entered clinic in Q3 (eight YTD); on track for 10+ in 2024; sonrotoclax & BGB-16673 in late-stage.
CEO cites strong momentum in hematology and solid tumor pipeline expansions globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.